Targeted Mass Spectrometry Reveals Interferon-Dependent Eicosanoid and Fatty Acid Alterations in Chronic Myeloid Leukaemia

Int J Mol Sci. 2023 Oct 24;24(21):15513. doi: 10.3390/ijms242115513.

Abstract

Bioactive lipids are involved in cellular signalling events with links to human disease. Many of these are involved in inflammation under normal and pathological conditions. Despite being attractive molecules from a pharmacological point of view, the detection and quantification of lipids has been a major challenge. Here, we have optimised a liquid chromatography-dynamic multiple reaction monitoring-targeted mass spectrometry (LC-dMRM-MS) approach to profile eicosanoids and fatty acids in biological samples. In particular, by applying this analytic workflow to study a cellular model of chronic myeloid leukaemia (CML), we found that the levels of intra- and extracellular 2-Arachidonoylglycerol (2-AG), intracellular Arachidonic Acid (AA), extracellular Prostaglandin F (PGF), extracellular 5-Hydroxyeicosatetraenoic acid (5-HETE), extracellular Palmitic acid (PA, C16:0) and extracellular Stearic acid (SA, C18:0), were altered in response to immunomodulation by type I interferon (IFN-I), a currently approved treatment for CML. Our observations indicate changes in eicosanoid and fatty acid metabolism, with potential relevance in the context of cancer inflammation and CML.

Keywords: bioactive lipids; cancer inflammation; cancer metabolism; chronic myeloid leukaemia; eicosanoids; fatty acids; innate immunity; lipidomics; mass spectrometry; type I interferon response.

MeSH terms

  • Eicosanoids / metabolism
  • Fatty Acids
  • Humans
  • Inflammation
  • Interferons
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Leukemia, Myeloid*
  • Tandem Mass Spectrometry / methods

Substances

  • Fatty Acids
  • Interferons
  • Eicosanoids

Grants and funding

H.C.S., S.D.D., Z.Y., B.M.K. and A.P.F. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant nr—2018-I2M-2-002). H.C.S., S.D.D., B.M.K. and A.P.F. are also funded by Pfizer Inc.